What they do: Biological Products, (No Diagnostic Substances) · Exchange: Nasdaq · Employees: 507
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. (via Yahoo Finance)
| Quarter end | Revenue | Diluted EPS |
|---|
Insiders hold: 0.49% · Institutions hold: 110.92% across 461 filers
| Institution | Shares | Value | % held |
|---|---|---|---|
| FMR, LLC | 20,852,907 | $1.39B | 14.01% |
| Jupiter Topco LLC | 17,965,847 | $1.20B | 12.07% |
| T. Rowe Price Investment Management, Inc. | 12,207,450 | $815.5M | 8.20% |
| Blackrock Inc. | 12,068,129 | $806.2M | 8.11% |
| RA Capital Management, L.P. | 11,474,599 | $766.5M | 7.71% |
| Wellington Management Group, LLP | 7,001,565 | $467.7M | 4.71% |
| Vanguard Portfolio Management LLC | 6,593,551 | $440.4M | 4.43% |
| Vanguard Capital Management LLC | 6,348,679 | $424.1M | 4.27% |
| Trade date | Filed | Name | Role | Action | Shares | Price | Value | Stock since |
|---|---|---|---|---|---|---|---|---|
| 2026-10-05 | 2026-10-07 | Cowan Elvia | SVP, Finance & CAO | OPTION EXERCISE | 19,000 | $25.92 | $492K | -9.5% |
| 2026-10-05 | 2026-10-07 | Cowan Elvia | SVP, Finance & CAO | SOLD | 19,000 | $86.74 | $1.6M | -9.5% |
| 2026-10-05 | 2026-10-07 | Wassil Jim | EVP, Chief Scientific Ofc, COO | OPTION EXERCISE | 18,000 | $5.35 | $96K | -9.5% |
| 2026-10-05 | 2026-10-07 | Wassil Jim | EVP, Chief Scientific Ofc, COO | SOLD | 18,000 | $86.74 | $1.6M | -9.5% |